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Schistosoma haematobium, a parasitic flatworm that infects more than 100 million people, mostly in the developing
world, is the causative agent of urogenital schistosomiasis, and is associated with a high incidence of squamous cell carci-
noma (SCC) of the bladder. During infection, eggs are deposited in the bladder causing an intense inflammatory reac-
tion. Angiogenesis is defined as the formation of new blood vessels from preexisting ones and is recognized as a key
event in cell proliferation and carcinogenesis and spread of malignant lesions. A growing amount of evidence points to
angiogenesis playing a key role in schistosomiasis-associated bladder cancer. Thus, identifying biomarkers of this process
plays an important role in the study of cancer. Here, we review recent findings on the role of angiogenesis in bladder
cancer and the growth factors that induce and assist in their development, particularly SCC of the bladder associated to
urogenital schistosomiasis.
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SCHISTOSOMIASIS
Schistosomiasis is a neglected tropical disease trans-
mitted to humans from freshwater snails. It is
caused by a blood fluke of the genus Schistosoma.
Schistosomiasis is considered the most important of
the helminthiases and the second most important
parasitosis, after malaria, causing high rates of
morbidity and mortality. As of 1989, schistosomia-
sis was endemic in 76 countries (1). Recent WHO
report declared schistosomiasis endemic in 78 coun-
tries (2, 3). S. haematobium is endemic in 53 coun-
tries in the Middle East and most of the African
continent, including the islands of Madagascar and
Mauritius. Due to successful eradication programs,
the infection is no more of significant public health
significance in Egypt, Lebanon, Oman, Syria, Tuni-
sia and Turkey because transmission is low or
nonexistent (4). A disputed and ill-defined focus
exists in India and requires further confirmation
(5). After more than 50 years in which no more
autochthonous cases of schistosomiasis were
recorded in Europe, S. haematobium infection has
recently emerged in Corsica (6). This disease affects
200 million people worldwide. From these, 20 mil-
lion have severe disease and 120 million are consid-
ered symptomatic. Risk of infection affects
600 million; others including travelers from devel-
oped countries (7).
This review focuses on the morphological vari-
ables and prognosis in carcinoma of the urinary
bladder associated with schistosomiasis, and the
fact that the appearance and formation of angio-
genesis alters the course of cancer development, in
the context of S. haematobium infection. The pre-
sent work attempts to integrate a variety of studies
and experimental approaches with S. haematobium
models, while giving particular emphasis to the
in vitro studies that have contributed to expanding
our understanding of the mechanisms of action of
growth factors and formation of new vessels in uri-
nary bladder cancer. In particular, we suggest that
the presence of eggs of S. haematobium plays a key
role in angiogenesis and contributes to the develop-
ment of urinary bladder cancer (Fig. 1).
UROGENITAL SCHISTOSOMIASIS
Three major species of schistosomes are the agents
of human schistosomiasis – Schistosoma japonicum
and Schistosoma mansoni cause intestinal
schistosomiasis in East Asia, Africa, South America
and the Caribbean, while S. haematobium, occur-
ring widely throughout Africa and the Middle East,
causes urogenital schistosomiasis. Recent recalibra-
tion of health burdens revealed that in the range of
4.5–70 million disability adjusted life years
(DALYs) are lost to schistosomiasis. More people
are infected with S. haematobium than with the
other schistosomes combined. Of 112 million cases
of S. haematobium infection in sub-Saharan Africa,
70 million are associated with hematuria, 18 million
with major urinary bladder wall pathology, and
10 million with hydronephrosis leading to kidney
damage (8–10). In many patients, deposition of
S. haematobium parasite ova eventually leads to
squamous cell carcinoma (SCC) of the urinary
bladder (11, 12). Accordingly, S. haematobium has
been classified as a Group 1 carcinogen by the
International Agency for Research on Cancer
(IARC) (13, 14).
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Fig. 1. Schematic representation of angiogenesis associated with urogenital schistosomiasis. Microphotographs from uri-
nary bladder sections stained with Hematoxylin and Eosin (4009).
SCHISTOSOMA HAEMATOBIUM-
ASSOCIATED URINARY BLADDER CANCER
Squamous cell carcinoma is a malignant, poorly
differentiated neoplasm. SCC is the common form
of urinary bladder cancer in rural Africa where
S. haematobium is prevalent (15, 16). By contrast,
the majority of urinary bladder cancer in develop-
ing countries and regions not endemic for urogeni-
tal schistosomiasis is transitional cell carcinoma
(TCC), which arises from the transitional epithe-
lium lining of the urinary bladder. The parasite
eggs trapped in the urinary bladder wall release
antigens and other metabolites (presumably evolved
to expedite egress to the urine, and hence to the
external environment). The phenomenon leads to
hematuria and to chronic inflammation, in turn
increasing the risk of SCC of the urinary bladder.
The epidemiological association between SCC of
the urinary bladder with schistosomiasis hematobia
is based both on case–control studies and on the
correlation of urinary bladder cancer incidence with
prevalence of S. haematobium infection within
diverse geographic locations. The incidence of uro-
genital schistosomiasis-associated SCC is estimated
in 3–4 cases per 100 000 (17). Schistosomiasis
hematobia is a chronic infection. The adult,
egg-producing schistosomes live for many years,
re-infections frequently occur, and schistosomiasis-
associated urinary bladder SCC appears relatively
early, often by the mid-decades of life (TCC usually
presents in the later decades of life). In its most
recent monograph, IARC confirmed that chronic
infection with S. haematobium causes cancer of the
urinary bladder (14).
The cellular and molecular mechanism linking
infection with S. haematobium and cancer is usually
related to adult parasite invasion in the venous
plexus around the urinary bladder, the eggs
released by worms, cause chronic granulomatous
inflammation of the mucosa and submucosa of the
urinary bladder. Chronic granulomatous inflamma-
tion and irritation subsequently leads to the devel-
opment of squamous metaplasia of the transitional
epithelium. Chronic granulomatous inflammation
also leads to fibrosis in the urinary bladder that
causes urinary stasis and super-infection by bacte-
ria. The bacteria convert the nitrates and nitrites in
dietary nitrosamines, which are then excreted in
urine. These nitrosamines are carcinogenic and act-
ing on metaplastic epithelium, promote subsequent
progression of squamous cell carcinoma. The infec-
tion can spread and involve the ureters and kid-
neys, causing chronic obstructive disorders and
kidney failure (18). Several models have been pro-
posed to explain the genesis of urinary bladder
cancer induced by Urogenital Schistosomiasis
(UGS). Some attribute initiation of carcinogenesis
to low doses of nitrosamines and/or other environ-
mental carcinogens associated with the infection. In
other models, it is suggested that UGS-induced car-
cinogenesis is due to exposure to tobacco smoke,
industrial and agricultural dyes and vitamin A defi-
ciency (19). However, the mechanism by which
infection contributes to carcinogenesis is still unre-
solved. Recent contributions suggest a crucial role
of S. haematobium: Chinese Hamster Ovary cells
(CHO) cells experimentally treated with parasite
antigens show increased proliferation, cell migration
and invasion, decreased apoptosis, increased Bcl-2
expression and reduced p27 expression. Altogether,
these biological processes are characteristic of
tumorigenesis and tumor cell survival (7). Further,
intravesical administration in a murine model of
S. haematobium extract induces urothelial dysplasia
(20), implying that infection by S. haematobium
induces malignant transformation of the urothe-
lium, even in the absence of nitrosamines. Previous
reports of our group revealed that schistosomes
produce estrogen metabolites called catechols and
that these molecules can be used as biomarkers for
the detection of schistosomiasis-associated urinary
bladder cancer (21–23). Based on this scientific evi-
dence, and the discovery of parasitic origin of estro-
gen metabolites, becomes fundamental to
understanding the role of this parasite as initiator
of carcinogenesis (24).
ANGIOGENESIS AND
LYMPHANGIOGENESIS IN URINARY
BLADDER CANCER
Angiogenesis, or the formation of new endothelial
sprouts from preexisting postcapillary venules, is a
well-known characteristic of inflammatory diseases,
wound repair and cancer (25, 26). Accordingly,
angiogenesis is a process in which endothelial cells
migrate and divide to form new capillaries, provid-
ing support for tumor progression. As such, much
attention has been focused on pathological signifi-
cance and detailed mechanism of the vascular sys-
tem and angiogenesis in cancer. Moreover, the
spread of tumor cells through the bloodstream and
lymphatic system plays an important role in metas-
tases development (26). A large number of pro-
angiogenic factors including vascular endothelial
growth factor (VEGF), basic fibroblast growth fac-
tor (bFGF), hepatocyte growth factor (HGF) and
angiogenin (ANG) are often overexpressed in
tumors (27). Several studies have indicated that
angiogenic activators play an important part in the
growth and spread of tumors. On immunohisto-
chemical examination, the VEGF family and their
receptors were found to be expressed in about half
of the human cancers investigated (28). These factors
are known to affect the prognosis of adenocarcino-
mas that have developed in the uterine cervix, (29),
endometrium, (30), ovary (31) and stomach (32). In
addition, a significant correlation between the
expression of VEGF and prognosis has been
described in colorectal cancer (33), breast cancer
(34), lung cancer (35), head and neck squamous cell
carcinoma (36), Kaposi sarcoma (37) and malignant
mesothelioma (38). These studies also indicated that
the levels of angiogenic factors in tissue reflect the
aggressiveness with which tumor cells spread, and
thus have predictive value in the identification of the
high-risk patients with poor prognosis.
Metastatic spread to regional lymph nodes is an
early step in systemic dissemination of tumors,
being usually associated with poor survival (39).
Moreover, exacerbated angiogenesis together with
presence of lymph node metastasis are poor prog-
nostic factors for transitional cell carcinoma and
urinary bladder carcinoma (40).
While both the blood and lymphatic vascular
systems have been implicated, preclinical experi-
mental systems supported by clinical evidence sug-
gest the most common pathway of initial metastasis
is through the lymphatic system (41). In recent
years, several works discuss the importance of
pathological lymphangiogenesis in urinary bladder
cancer and in its importance in the invasiveness
toward adjacent muscle tissue (42–44). Similarly,
recent reports evidence the activation of VEGF sig-
naling that controls and promotes lymphangiogene-
sis by several parasites such as filariasis and
leishmaniasis agents (45, 46). Although lymphan-
giogenesis is shown to be increased in both urinary
bladder cancer and in infection caused by parasites,
it is a question needed to be answered whether lym-
phangiogensis would be involved in urinary bladder
cancer associated with schistosomiasis.
SCHISTOSOMIASIS AND ANGIOGENESIS
Angiogenesis plays a complex and extraordinary
role in schistosomiasis. This statement may seem a
paradox, since schistosomes are intravascular para-
sites that cause damage by destroying the blood
vessels (47). Angiogenesis plays an important role
during the formation of perioval granulomas as
well as in the genesis of schistosomiasis fibrosis.
From the point of view of general pathology, schis-
tosomal perioval granulomas are dynamically simi-
lar to the healing of wounds, with the production
of granulation tissue, which becomes increasingly
less vascularized with time (48).
It has been demonstrated that intact live eggs,
excretory/secretory products of eggs and the
extracts of homogenized eggs stimulate the prolifer-
ation and migration of endothelial cells. Formation
of endothelial capillary-like outgrowths, was stimu-
lated by egg extracts (49). The effects mediated by
eggs of schistosomes revealed that the soluble egg
antigen induces endothelial cell proliferation and
upregulates vascular endothelial growth factor
(VEGF) (47). Loeffler et al. (50) investigated the
effects of Schistosoma mansoni soluble egg antigen
(SEA) on angiogenic processes: proliferation, tube
formation and apoptosis of human umbilical vein
endothelial cells (HUVECs). In this study, SEA
increased HUVEC tube formation and decreased
HUVEC apoptosis after serum and growth factor
deprivation. These authors showed that messenger
RNA for vascular endothelial growth factor
(VEGF) increased 2-fold in SEA-treated HUVECs.
Their findings suggest that products secreted by
schistosome eggs may promote angiogenesis by
upregulating endothelial cell VEGF (50). Other
authors analyzed VEGF levels in sera from people
diagnosed with schistosomiasis. These patients had
significantly high VEGF levels compared with
healthy people (51, 52). Therefore, this angiogenic
capacity has been suggested as an early marker of
preneoplastic and neoplastic lesions in schistosomi-
asis associated SCC (53). Several growth factors
and other molecules produced by the schistosome
itself have been reported to be associated with
tumor growth, progression and survival of urinary
bladder cancer. Moreover, tumor microvessel
density (MVD) is thought to be the most useful
prognostic marker for cancer development, the
relapse-free survival and overall survival (54).
El-Sobky and collaborators (55) found a significant
relationship between angiogenesis and tumor grade.
These findings suggest that assessing angiogenesis
using the MVD provides an independent predictor
of survival in patients with schistosome-associated
carcinoma of the urinary bladder.
Studies to quantify the concentration of angio-
genic factors in cases of SCC of the urinary bladder
associated to schistosomiasis may be of great clini-
cal importance for urinary bladder cancer detection,
assessing their stage and level of development. The
methodologies that can be performed to evaluate
angiogenesis associated with S. haematobium infec-
tion are by means of microscopy/immunochemical,
ELISA, PCR-based techniques and other molecular
biology techniques that can be used to evaluate vas-
cularization markers in both samples of infected
patients and in animal models. Such markers may
include CD31, CD34, vonWillebrand factor (vWF)
and VGFRs. Angiogenic markers showed signifi-
cant association with clinical stage (27). It was
reported that Basic fibroblast growth factor
(bFGF) increased significantly in urinary bladder
squamous cell carcinoma cases. These authors
found that bFGF and hepatocyte growth factor
(HGF) significantly correlated with tumor grade
(27). Understanding the growth factors that influ-
ence the progression of angiogenesis and lymphan-
giogenesis during infection by schistosomes
becomes feasible from the point of view of a possi-
ble intervention in the spread of tumor cells. More-
over, cancers are genetically diversified using
different exposures, DNA repair effects and cellular
origin, which may suggest that a particular expo-
sure (parasite antigen) can lead to a cascade of
events that promote cancer in susceptible hosts,
and that angiogenic factors, as reported in
S. haematobium, could be used as diagnostic and
prognostic markers of urinary bladder cancer in
UGS. An in the case of Symmers’ fibrosis associ-
ated to schistosomiasis, angiogenesis inhibitors are
indicated as an effective tool for the treatment of
this liver fibrosis (55).
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
In the last years, urinary bladder cancer-associated
schistosomiasis has been a field under extensive
investigation. Increasing knowledge in the field has
opened up important new perspectives with respect
to how this type of cancer is perceived. Among
them, there are crucial findings on the hallmarks
of cancer and the contribution of these to the car-
cinogenic process, specially angiogenesis and lym-
phangiogenesis. On the basis of these results, a
new mechanistic approach to the development of
schistosomiasis-associated urinary bladder cancer
arose, enabling us to further comprehend their
underlying molecular mechanisms and contribution
to the development of this type of cancer. Studies
are needed to identify and characterize angiogenic
and lymphangiogenic markers in carcinoma of the
urinary bladder associated to UGS. Tumor induc-
tion, proliferation, invasion and metastasis repre-
sent a complex and incompletely understood series
of events (56). Thus, the development of addi-
tional biological markers of prognosis for tumor
angiogenesis and lymphangiogenesis, may add
information to the initial risk assessment. It is to
be hoped that the rapidly increasing volume of
information in these field can be used in the future
to develop specific and more effective anti-cancer
therapies, not only toward schistosomiasis-
associated urinary bladder cancer but also other
types of cancer.
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